Stock News•2 months ago
ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus
Altimmune narrowed its Q2 loss, with $519M in cash funding operations into 2029, as pemvidutide progresses in liver and alcohol-use disorder studies.
MarketLens
Altimmune's $225 Million Capital Raise: A Necessary Lifeline
6 months ago
SHARE THIS ON:
Exclusive Content for Pro Members
Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.
SHARE THIS ON:
Related Articles
What's Driving Itron's Latest Capital Raise
8 months ago
Category
You may also like
Stock News•3 months ago
Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants
Q32 Bio priced a $200M public offering of ~11M shares and pre-funded warrants at $18.25/share, diluting existing holders to fund clinical development.
Stock News•3 months ago
Alvotech further strengthens liquidity by securing term loan facility of $75 million
Alvotech secured a $75 million term loan facility via an amended credit agreement with GoldenTree Asset Management, strengthening its liquidity position.
Breaking News
View All →Featured Articles
Top Headlines
Stock News•20 minutes ago
GOOGL, GOOG Investors Have Opportunity to Lead Alphabet Inc. Securities Fraud Lawsuit
Stock News•1 hour ago
CrowdStrike Holdings (CRWD) Laps the Stock Market: Here's Why
Stock News•1 hour ago
Nvidia (NVDA) Surpasses Market Returns: Some Facts Worth Knowing
Stock News•1 hour ago
Apple (AAPL) Stock Falls Amid Market Uptick: What Investors Need to Know
Stock News•1 hour ago